Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Hongyun Zhao(Sun Yat-sen University), Li Zhang(Fox Chase Cancer Center), Caicun Zhou(Tongji University), Baohui Han(Shanghai Jiao Tong University), Ying Cheng(Jilin Province Tumor Hospital), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Fan(Zhejiang Cancer Hospital), Shucai Zhang(Northeastern University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheng Huang(Army Medical University), Xiangqun Song(Tumor Hospital of Guangxi Medical University), Shenglin Ma(North University of China), Yunpeng Liu(Shenyang Institute of Automation), Xiaoqing Liu(Chinese PLA General Hospital), Shujun Yang(Henan Cancer Hospital), Shun Lü(Shanghai Jiao Tong University)
Journal of Thoracic Oncology
January 15, 2015
10.1097/jto.0000000000000445
Cited by 44

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k